Transplantation of fetal liver tissue coated by ultra-purified alginate gel over liver improves hepatic function in the cirrhosis rat model

Rong Qiu,Katsutomo Oshiro,Soichiro Murata,Hideki Taniguchi,Yumi Hatada

doi:10.1038/s41598-020-65069-y

Rong Qiu, Katsutomo Oshiro + Show 3 more

Open Access

https://doi.org/10.1038/s41598-020-65069-y

Copy DOI

Abstract

In this study, we used a new coating agent, that is, ultra-purified alginate gel (UPAL), for fetal liver tissue transplantation. This study aims to compare the effect of UPAL with the effect of other coating agents on improving the effect of fetal liver tissue transplantation in a liver cirrhosis rat model. Prior to the transplantation of wild-type ED14 fetal liver tissues, various coating agents were separately applied on the liver surface of rats with cirrhosis. Then, we compared the engraftment area, engraftment rate and liver function level of these rats. As a result, coating the liver surface of a cirrhosis rat with UPAL obtained the best effect in terms of engraftment area and engraftment rate of the transplanted liver tissue and in the recovery of liver function compared with control group. Therefore, UPAL coating may serve as a novel strategy for liver organoid transplantation.

Highlights

In this study, we used a new coating agent, that is, ultra-purified alginate gel (UPAL), for fetal liver tissue transplantation
Dipeptidyl peptidase-IV (DPPIV) is a membrane-associated peptidase, known as CD26, that is widely used as marker for hepatocytes in several liver diseases, such as primary biliary cirrhosis and hepatocellular carcinoma (HCC)[14,15]
Histological sections stained with Sirius red and liver function parameters of the DMN-induced liver cirrhosis in rats

Summary

Introduction

We used a new coating agent, that is, ultra-purified alginate gel (UPAL), for fetal liver tissue transplantation. This study aims to compare the effect of UPAL with the effect of other coating agents on improving the effect of fetal liver tissue transplantation in a liver cirrhosis rat model. Several alternative treatments, such as medication, bone marrow cell[9] transplantation and adipose tissue-derived stromal cell[10] (collected from the patient) transplantation, have been proposed to treat end-stage liver cirrhosis None of these treatments shows similar efficacy to the traditional liver transplantation method. Bone marrow cell transplantation somehow manages to improve liver function, but the transplanted cells failed to differentiate into fully functioned liver tissues[9] Some medicines, such as PRI-724 (a CBP/β-Catenin inhibitor), are proven effective in improving liver histology and Child-Pugh scores in several patients with hepatitis C virus-related cirrhosis, but they still cannot cure the disease[11]. Different coating materials were used to cover the transplanted fetal rat liver tissue

Objectives

Methods

Results

Conclusion